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ABSTRACT
Introduction: Patients with gout have
numerous comorbidities. We aimed to
estimate the prevalence and incidence rates of
renal and cardiovascular morbidities in
trial-aligned patients with established gout in
Germany (DE), the United Kingdom (UK), the
United States (US), and France (FR).
Methods: This longitudinal cohort study used
retrospective data from IMS Disease AnalyzerTM
(DE, FR), Clinical Practice Research
Datalink–Hospital Episode Statistics (UK), and
IMS’ PharMetrics Plus database linked with
outpatient laboratory results (US). Included
patients were C18 years at index date (January
1, 2010; all dates ?1 year for FR), with
continuous enrollment during the pre-index
year, had ‘‘prevalent established gout’’
determined by data in the pre-index year, and
C1 documented visit after index date;
additional inclusion/exclusion criteria were
aligned with recent gout clinical trials.
Look-back for comorbidity prevalence
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extended to January 1, 2003 (US: January 1,
2009). Follow-up for incidence extended from
index date to at most March 26, 2013 (FR: May
31, 2014). Events of interest were identified by
diagnostic codes and/or laboratory data.
Results: The trial-aligned cohorts included
35,118 (DE), 24,607 (UK), 121,591 (US), and
17,338 (FR) patients. Among renal conditions,
baseline diagnosis of chronic kidney disease/
renal failure was most prevalent in the UK
followed by DE; abnormal serum creatinine was
most prevalent in the UK. Hypertension was the
most prevalent cardiovascular diagnosis in all
countries, followed by ischemic heart disease
(IHD) and myocardial infarction. Incidence
rates (per 100 patient-years) for new/worsening
renal impairment ranged from 1.67 (DE) to 4.34
(US) and for nephrolithiasis diagnosis from 0.31
(FR) to 3.79 (US). The incidence rates for
hypertension diagnosis were highest among
cardiovascular-related events, ranging from
3.23 (UK) to 20.27 (US), followed by IHD.
Conclusions: Patients with established gout
such as those included in gout trials have a
high burden of established morbidity and new
diagnoses of morbid events. Consideration of
comorbidities, which greatly exacerbate disease
burden, is important in gout management.
Funding: AstraZeneca.
Keywords: Cardiovascular; Comorbidities;
European Union; Gout; Incidence; Prevalence;
Renal; Serum uric acid; United States
INTRODUCTION
Gout is a urate crystal deposition disease that,
when uncontrolled, is characterized by
recurrent attacks (gout flares) of acute
inflammatory arthritis of the peripheral joints.
Continued urate crystal deposition due to
uncontrolled disease can also lead to painful
and disfiguring tophi, kidney stones, and uric
acid nephropathy. Gout is the most common
type of inflammatory arthritis in men and
postmenopausal women, affecting 1–4% of the
Western developed population [1, 2]. Gout is a
chronic, progressively degenerative disease, and
even when the patient is not experiencing flares
or other signs and symptoms, the disease is
ongoing and worsening. If not appropriately
treated, gout can cause permanent joint
destruction, bone erosion, and kidney damage
[3, 4].
Risk factors for gout include dietary
contributors, alcohol consumption, use of
thiazide diuretics, and metabolic-related
diseases (e.g., obesity, arterial hypertension,
diabetes, hypercholesterolemia, coronary
artery disease, congestive heart failure, and
renal failure), as well as a genetic component,
and in women, menopause [5]. The hallmark
precursor to gout is hyperuricemia (serum uric
acid [sUA] levels of[6.8 mg/dL [ 400 lmol/L],
i.e., the precipitation concentration for urate
crystals) [6]. Hyperuricemia leads to the
deposition of monosodium urate crystals
(MSU) in musculoskeletal structures including
joints, in kidneys, and in other connective
tissue [7]. While diet and overproduction of
uric acid can contribute (10%), the
predominant cause of hyperuricemia is
inefficient uric acid excretion (90%) [8]. A
proportion of individuals may have both an
overproduction and an inefficient excretion of
uric acid [9].
In most patients, gout cannot be effectively
treated by lifestyle changes alone. For long-term
pharmacologic management of gout, the
treatment guidelines from the European
League against Rheumatism [4], the British
Society of Rheumatology [10], and the
American College of Rheumatology (ACR) [11]
recommend treatments aimed at decreasing
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sUA for patients with recurrent acute attacks,
tophi, or radiographic gout changes. Effective
urate-lowering treatment (ULT) maintains uric
acid below the critical level, prevents further
MSU crystal formation, and over time dissolves
away existing crystals [4]. The 2012 ACR
Guidelines suggest xanthine oxidase inhibitor
therapy with allopurinol or febuxostat as the
first-line pharmacologic approach. In case
first-line therapies do not succeed in reaching
sUA targets or are contraindicated, uricosuric
agents that increase renal excretion of uric acid
(such as probenecid, sulfinpyrazone,
benzbromarone, isobromindione) can be used
[12]. Lesinurad increases urinary uric acid
excretion and was recently approved in the US
and EU to be used in combination with a
xanthine oxidase inhibitor in patients unable
to achieve target sUA on a xanthine oxidase
inhibitor alone [13–15].
Hyperuricemia and gout are associated with
comorbidities such as cardiovascular disease,
chronic kidney disease (CKD), and metabolic
syndrome including its components diabetes
and hypertension [5, 16–24]. Patients with
frequent gout attacks have higher prevalence
of comorbid diseases, (e.g., CKD, hypertension,
dyslipidemia, ischemic heart disease (IHD),
heart failure, and arthritis) than those with
infrequent attacks [25]. In addition, previous
research has identified that morbidities
associated with gout are directly related to
gout disease severity [26]. Treatment
challenges arise when patients have comorbid
conditions and are being treated with multiple
medications; these challenges include
drug–drug interactions with treatments for
renal disease or hepatic impairment, as well as
with statins for the treatment of
hypercholesterolemia [27–29]. Studies show
that many patients with gout do not achieve
treatment goals with current therapies, and the
majority continue to experience recurrent acute
attacks, further joint damage, and other
complications [30]. Understanding morbidity
prevalence and incidence rates in patients with
gout is important for benchmarking optimal
approaches to gout management and selecting
optimal treatments for individual patients.
Patients with gout commonly have multiple
comorbidities, with subsequent comorbidities
arising as a result of the disease; this should be
taken into consideration both in clinical
practice and when conducting clinical trials in
these patients. In this study, we analyzed the
prevalence and incidence rates of potential
disease- or treatment-related renal and
cardiovascular morbidities in patients with
established gout from databases in four
countries, with eligibility criteria aligned with
recent gout clinical trial inclusion criteria [31,
32] to provide a more appropriate context or
baseline for understanding clinical trial rates
of morbidities. CLEAR 1 (NCT01510158)
and CLEAR 2 (NCT01493531) were two
placebo-controlled, phase 3 trials that
investigated the efficacy and safety of
lesinurad (a selective uric acid reabsorption
inhibitor) in combination with allopurinol in
gout patients having an inadequate response to
standard-of-care allopurinol, and were used
here to help define cohort exclusion criteria
and standardize age/sex distributions for the
database study. The current analysis comprises
data from patients in Germany (DE), the United
Kingdom (UK), the US, and France (FR).
METHODS
Data Sources
This study uses a retrospective data analysis of
patients with gout using health-care data
extracted from electronic medical record and
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administrative claims databases. The following
databases were used: DE—IMS Disease
AnalyzerTM (IMS Health, Danbury, CT, US)
databases [33, 34]; UK—Clinical Practice
Research Datalink (CPRD) Hospital Episode
Statistics [18, 35]; US—IMS PharMetrics Plus
database [36–38]; FR—IMS Disease Analyzer
database [39, 40]. A more detailed description
of these databases can be found in Table 1.
Study Design and Patients
Study Design
A longitudinal cohort study design was used to
evaluate (1) established prevalent comorbidity
and (2) prospective incident comorbidity, in
patients with prevalent established gout and
eligibility criteria aligned with recent gout
clinical trials.
Observation Periods
The overall study design is illustrated in Fig. 1.
For the US, the UK and DE, the cohort baseline
(index date) was January 1, 2010. For the FR
analysis, the timeline was moved forward by
1 year (index date January 1, 2011) to
synchronize with the supplementary
information obtained by primary data
collection (only available for 2012 and 2013,
see details below). The 12-month period
immediately preceding the index date was
defined as the pre-index year and was used to
identify eligible patients and determine most
baseline characteristics. For determining some
baseline comorbidities, the pre-index look-back
was extended to January 1, 2003, in UK and DE
(2004 in FR). The period following the index
date was the follow-up period, and extended for
each particular analysis to the first of the
following occurrences in each patient:
disenrollment, end of the study period, or an
event of the outcome being studied in that
particular analysis. The study end dates (i.e., last
data available) were: DE: February 28, 2013; UK:
March 26, 2013; US: December 31, 2012; FR:
May 31, 2014.
To investigate morbidity potentially
associated with current gout treatments,
ULT-treated cohorts of patients treated with
allopurinol, or with febuxostat, were also
defined (Fig. 1). The first ULT treatment episode
initiated after the main index date constituted
the cohort entry criterion and defined the
treatment episode index date. A treatment
episode pre-index year and extended pre-index
look-back were defined from the treatment
episode index date. Follow-up for this cohort
continued while on this first defined ULT
treatment, i.e., until a switch or an add-on
occurred or treatment disruption for a duration
longer than the ‘‘admissible gap’’ (50% of the
previous script’s duration), which terminated the
first treatment episode, or otherwise until an
event occurred, or until disenrollment, or the
end of the study period. Dose change was not
considered a treatment episode termination.
Patient Inclusion and Exclusion Criteria
Since we aimed to investigate morbidity in a
gout trial-aligned prevalent established gout
cohort, inclusion criteria for the prospective
cohort analysis included having prevalent
established gout on the main index date (as
assessed during the 1-year main pre-index
period), being aged C18 years on the main
index date, being continuously enrolled in the
database during the pre-index year, and having
at least one observation in the database after the
index date (Fig. 2).
Established gout was defined as: at least one
prescription of ULT documented during the
pre-index year, or eligible for ULT according
to ACR guidelines (i.e., a gout diagnosis
documented during the pre-index year
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combined with either evidence of moderate
CKD, diagnosis code for urolithiasis, diagnosis
code for tophus, or occurrence of two gout
flares).
Exclusion criteria included: at least one
diagnosis during the pre-index year of
hematological cancer, severe renal
impairment, tumor lysis syndrome,
Table 1 Data sources
Country Database Description of data source
Germany
(DE)
IMS Disease Analyzer (DA) databases A longitudinal EMR database providing anonymized
longitudinal data on consultations, diagnoses, and
treatment within primary care and referrals to secondary
care as recorded by various panels of physicians (grouped
per specialty) on their practice computers. In the context of
this study, the data used were limited to the ﬁve panels with
the highest proportion of gout patients, i.e., GPs (including
diabetologists), rheumatologists, urologists, dermatologists,
and neurologists. The database represents 2.4% (N = 2500)




Clinical Practice Research Datalink linked
to Hospital Episode Statistics
(CPRD-HES)
CPRD collates computerized EMR data from GPs at[60%
of practices across the whole country and includes
demographic information, prescription details, clinical
events, diagnoses, referrals to secondary care (specialists or
hospitals), and major outcomes. Linked to HES, a database
containing inpatient data from all NHS hospitalizations,
including date of admission and discharge, main discharge
diagnoses, and main procedures. The linked CPRD-HES




IMS PharMetrics Plus database A database comprising adjudicated health plan claims for
more than 150 million unique anonymous enrollees
including detailed information on patient demographics,
inpatient/outpatient diagnoses and procedures, prescription
records, and corresponding amounts paid by health plans.
Additional information on laboratory results was obtained
for a subset of the cohort through a linkage with external
data provided by a leading national laboratory network
France (FR) IMS DA database A French version of the DA database, quite similar to its
German equivalent but limited to GPs and not including
referrals to secondary care. In this study, additional
information was included for hospitalizations and
laboratory results collected through an observational survey
study conducted in a subset of the GPs present in the
database
GP general practitioner; EMR electronic medical record
1184 Adv Ther (2016) 33:1180–1198
Lesch–Nyhan syndrome or juvenile gout,
missing data for important variables, or a
payer type of ‘‘Medicare Cost’’ or ‘‘State
Children’s Health Insurance Program’’ (US
only) (Fig. 2). Additional exclusion criteria
applied to identify patients meeting similar
criteria to those used in recent gout clinical
trials [31, 32] (‘‘gout trial-aligned prevalent
established gout’’) included: history of
myositis/myopathy or rhabdomyolysis; C1
prescription for systemic immunosuppressive/
immunomodulatory treatment; treatment of
active peptic ulcer disease within 4 weeks of
index date; treatment with valproic acid or
other known inhibitors before epoxide
hydrolase within 90 days of the main index
date; or C1 diagnosis code for HIV infection,
hepatitis B or C infection, malignancy,
unstable angina, heart failure, myocardial
infarction, stroke, deep vein thrombosis, active
liver disease, or hepatic dysfunction.
Morbidity
Identification of morbidity was primarily
based on diagnostic codes at one inpatient
(hospitalization) or outpatient visit
(International Classification of Diseases, Ninth
Revision, Clinical Modification [ICD-9-CM] for
US, Read/ICD-10 for UK, ICD-10 for FR and DE)
and/or laboratory data (C1 laboratory result
during time period of interest), depending on
the outcome of interest.
Morbidities of interest included CKD/renal
impairment (pre-index for prevalence:
diagnosis-based C1 diagnosis of CKD CStage 2
or acute renal failure, or laboratory-based C1
elevated serum creatinine [sCr]; post-index for
incidence: diagnosis-based new or worsening
Fig. 1 Longitudinal cohort study design. DE Germany, UK United Kingdom, US United States, FR France
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Fig. 2 Patient attrition. aAssessed in the 1-year pre-index period. DE Germany, UK United Kingdom, US United States,
FR France
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renal impairment identified through diagnosis
codes, or laboratory-based relative increase in
sCr of C1.59 over baseline), nephrolithiasis,
cardiovascular conditions (essential
hypertension, myocardial infarction, heart
failure, IHD, pulmonary embolism, deep vein
thrombosis), and diabetes. For FR,
complementary observational data on
hospitalizations and selected laboratory data
(otherwise unavailable in the database) were
collected retrospectively for a subset of the
patients extracted from the database, based on
voluntary participation by the general
practitioners (GPs). Seventy-nine GPs
participated, providing additional information
on 943 patients. For FR, inpatient
hospitalization data were thus unavailable for
most patients and therefore outcomes that
often require hospitalization may be
underestimated for FR.
Statistical Analyses
Analyses are presented for the overall gout
trial-aligned prevalent established gout cohort
and for morbidity analyses also by first ULT
treatment (allopurinol, febuxostat) in the
period following the main index date.
For baseline demographics and patient
characteristics, categorical measures are
presented as frequency (number of cases) and
percentage of the total study population
observed. For continuous variables, descriptive
statistics are presented.
To obtain rates relevant for gout clinical trial
context, the prevalence and incidence rates
were standardized to the approximate age and
sex distribution of a gout trial population [31,
32] to account for the difference in age and sex
distributions between such a prevalent
established gout trial population and the
observational gout trial-aligned prevalent
established gout cohorts in this study. Crude
observational cohort rates are also presented in
Supplementary Tables.
To describe the baseline comorbidity of the
cohorts, frequency (number of cases) and
prevalence rates (percentage) standardized to
the age and sex distribution of gout clinical trial
patients are presented, of patients with C1
event (diagnosis and/or laboratory results) for
each respective condition documented at any
time in the 1 year pre-index in the US, and for
pulmonary embolism and deep vein thrombosis
in FR, DE, UK, or from January 1, 2003 (2004 in
FR) for the remaining morbid events in FR, DE,
and UK, until the main index date (or
treatment-related index date, respectively).
The incidence of morbidities related to
laboratory values were assessed only in the
subgroup of subjects with available laboratory
data (i.e., subjects with linkable laboratory
values). For the US, laboratory data were
obtained for an external linkable source and
were available for a subsample of 8% of the
patients with gout used for this study. For the
UK and DE, all laboratory tests were in
principle available for all subjects, so the
absence of a test indicates it was not
performed. For FR, laboratory tests for the
outcomes studied were not systematically
available (see details above).
Age- and sex-standardized incidence rates for
each morbidity event are presented per 100
person-years (PY), with 95% confidence
intervals. Follow-up for each event analysis
started from the index date and ended at the
occurrence of the first event (for patients with
an event), death, disenrollment from the health
plan (for subjects not experiencing the event),
or the study end date.
Hypertension, heart failure, IHD, and
diabetes were considered as chronic
conditions, while all other studied morbidities
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were considered as acute. Patients with
prevalent chronic morbidities at index date
were excluded from the analysis of incidence
post-index of these morbidities. The incidence
of the acute conditions in the post-index period
was evaluated independent of their occurrence
in the pre-index period.
Data were analyzed using SAS software
version 9 (SAS Institute, Cary, NC, USA).
Compliance with Ethics Guidelines
This article is based primarily on previously and
routinely collected data in the databases used
for the study, in compliance with the rules for
each database. The UK part of this study was
approved by the Independent Scientific
Advisory Committee for MHRA database
research (ISAC) under protocol number
13_134, as required for use of CPRD data.
Some complementary retrospective data were
collected in France from a sample of general
practitioners participating in the French Disease
Analyzer database, with approval obtained from
the ‘‘CNIL’’ (‘‘Commission Nationale de
l’Informatique et des Liberte´s’’, ref: MMS/MKE/
AR/144351). Beyond this, the current report
does not involve any new studies of human or




In total, 71,622 (DE), 44,775 (UK), 313,311 (US),
and 29,645 (FR) patients were identified with
prevalent established gout as defined during the
main pre-index year. After applying trial-aligned
inclusion and exclusion criteria, the gout
trial-aligned prevalent established gout cohorts
comprised a total of 35,118 (DE), 24,607 (UK),
121,591 (US), and 17,338 (FR) patients (Fig. 2).
The characteristics of the gout trial-aligned
prevalent established gout cohort at baseline,
on the index date, are shown in Table 2.
Patients from DE, the UK, and FR were similar
with regard to age and body mass index (BMI),
while patients from the US generally were
younger. BMI was unavailable for US patients,
and only available for a minority of patients in
the other countries. Patients from the UK had
the highest mean number of days on ULT
during the 1-year pre-index period.
Several studied groups of co-medications of
interest with respect to the outcomes studied
were found to be common in the pre-index year
(Table 2) [41]. Approximately, 22–38% of
patients across countries were treated with
diuretics and angiotensin-converting enzyme
inhibitors, respectively. Drugs considered to
potentially be associated with sUA decrease
were taken by a large majority, 63–82%, and
almost all patients were taking some drug with
potential nephrotoxic effects.
Prior to the index date, a recorded diagnosis
of essential hypertension was most prevalent in
patients from DE and least prevalent in patients
from the UK (Table 2). Obesity was most
prevalent in patients from the UK and diabetes
was most prevalent in patients from DE.
Standardized Prevalence Rates of Morbid
Events
Standardized prevalence rates of morbidity
events potentially associated with gout or gout
treatment are presented in Table 3; for
corresponding crude rates, see Table S2 in the
supplementary materials.
Among renal conditions, diagnosis of
CKD/renal failure was most prevalent in the
1188 Adv Ther (2016) 33:1180–1198
UK (10.9%) followed by DE (6.7%);
prevalence of abnormal sCr was also highest
in the UK (30.6%). Hypertension was the
most prevalent cardiovascular diagnosis in all
four countries, followed by IHD and
myocardial infarction.
Table 2 Demographic and clinical characteristics of the study patients in gout trial-aligned prevalent established gout
cohorts in databases in four countries









Mean age (SD) 66.7 (12.3) 64.8 (13.1) 55.9 (11.5) 67.2 (12.5)
Male, % 72.7 85.7 86.5 75.1
Mean BMI (SD)a 31.4 (5.5) 31.0 (5.2) N/Ab 30.0 (5.7)
Mean number of days on ULT during the pre-index
period (SD)
223.4 (113.1) 285.6 (106.8) 197.9 (126.6) 157.7 (128.3)
Co-medicationsd taken during the 1-year pre-index period:
Diuretics, % 37.1 28.0 24.2 20.7
ACE inhibitors, % 35.5 37.6 36.5 21.7
Drugs associated with a potential risk of renal
insufﬁciency/nephrotoxicitye, %
99.5 99.7 89.6 99.9
Drugs potentially associated with sUA decreasef, % 67.9 63.1 71.4 81.6
Comorbidities during the 1-year or extended pre-index period:
Hyperlipidemia, %g 43.6 54.4 44.1 49.2
Essential hypertension, %h 70.4 32.4 56.6 42.4
Obesity, %g 8.6 24.8 6.7 6.8
Diabetesc, %h 36.9 16.0 23.0 15.0
ACE angiotensin-converting-enzyme, BMI body mass index, DE Germany, FR France, NSAID nonsteroidal
anti-inﬂammatory drug, SD standard deviation, sUA serum uric acid, UK United Kingdom, ULT urate-lowering
treatment, US United States
a Average value observed during the 1 year prior to index date for patients with available BMI values. BMI data were
available for 10.2% of German, 46.6% of UK, and 15% of French patients
b Data not available for US patients (only categorical data based on diagnosis codes available for a subset; 95.7% of patients
with available BMI values had BMI C30)
c One diagnosis or one prescription of anti-diabetic drug
d See Table S2 in the supplementary materials
e Includes NSAIDs, ACE inhibitors, diuretics, interleukin inhibitor, aminoglycoside antibacterials, beta-lactam
antibacterials and penicillins, short-acting sulfonamides, hormonal contraceptives for systemic use, estrogens,
progestogens, direct acting anti-viral drugs, platinum compounds (chemotherapeutic agents), interferons, angiotensin II
antagonists and related combinations, statins, X-ray contrast media, paramagnetic contrast media, and a few other drugs
f Includes various drugs from Daskalopoulou et al. [41], hormonal contraceptives for systemic use, estrogens, and
progestogens
g During the 1-year pre-index period
h During 7 years before index date for DE, UK, and FR; 1-year pre-index for US
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Standardized Incidence Rates of Morbid
Events
Standardized incidence rates (per 100 PY) of
diagnosis-based morbidity events potentially
associated with gout or gout treatment in the
gout trial-aligned prevalent gout cohort are
presented in Table 4; for corresponding crude
rates, see Table S3 in the supplementary
materials.
Estimated standardized incidence rates of
new/worsening renal impairment ranged from
1.67 (DE, overall group) to 21.72 (US,
febuxostat-treated), with that of
nephrolithiasis diagnosis ranging from 0.12
(FR, overall group) to 5.65 (US,
allopurinol-treated). The incidence rate of
hypertension diagnosis was highest among
cardiovascular-related rates in all groups,
ranging from 3.23 (UK, overall group) to 39.46
(US allopurinol-treated), followed by IHD.
Relatively low numbers of patients in the
febuxostat cohort resulted in wide confidence
intervals (Table 4).
For laboratory-based renal impairment, the
incidence rates of sCr elevations of C1.59 over
the pre-index baseline in these data with likely
underreporting were 0.49 (FR), 0.71 (US), and
0.84 (UK, DE) in the overall cohort, in the
subgroups with available laboratory data.
DISCUSSION
Patients with gout frequently have multiple
comorbidities, including hypertension, CKD,
cardiovascular disease, obesity, diabetes, and
hyperlipidemia, all of which have a significant
adverse impact on public health [25, 42]. In
some cases (e.g., CKD), the presence of the
comorbidity contributes to the progression of
hyperuricemia and/or gout [43]. Whether gout
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pathogenesis of gout comorbidities is an area of
intensifying investigation.
The results presented herein confirm that
there is a notable degree of comorbidity burden
among patients with gout. In agreement with
other studies [26, 44], hypertension was the
most prevalent cardiovascular diagnosis in gout
patients, but there was also a high percentage of
patients from each country with hyperlipidemia
and/or diabetes. The clinical characteristics of
the patients in this study were similar to those
described in another recent large US
population-based study of 36,431 patients
with chronic gout [42] treated with
allopurinol, febuxostat, or colchicine in which
more than half had hypertension and
hyperlipidemia, 19–23% had diabetes, and
9–12% had cardiovascular disease. As gout is
known to increase the risk of mortality from
cardiovascular disease and coronary heart
disease [18], and higher cardiovascular risk is
associated with the severity of gout [45], it is
important to correctly identify and manage
cardiovascular risk factors in patients with
gout, and also to identify and optimally
manage gout in patients at risk of
cardiovascular disease. The findings from this
study also demonstrate that patients with gout
are subsequently diagnosed with other
morbidity events.
Conclusions regarding differences between
the two ULT treatment cohorts are difficult to
draw due to the relatively low numbers of
patients in the febuxostat cohort. A previous
study reported that CKD was twice as common
in febuxostat initiators compared with
allopurinol or colchicine initiators [42] and
that febuxostat initiators had more comorbid
conditions, greater use of medications and
health care resources compared with the other
groups. This may be due to the fact that
febuxostat is generally used as the second-line
treatment after allopurinol and therefore
patients are more likely to have more severe
disease and/or comorbidities than those
receiving first-line treatment. In our study, we
noted numerically higher standardized CKD/
renal prevalence in the febuxostat than in the
allopurinol cohort as the only consistent
difference across countries for prevalence rates,
while there was no consistent difference
between the treatments for incidence of
new/worsening renal impairment.
The associations between gout and
occurrence of several comorbidities are well
established [21]. For example, the association
between gout and the components of metabolic
syndrome can be explained, in part, through
effects on urate production, renal angiotensin
secretion, and renal urate excretion [46, 47].
Gout is also a known risk factor for
cardiovascular diseases such as cerebrovascular
disease, congestive heart failure, and
myocardial infarction [48–51], collectively
leading to an increased risk for all-cause and
cardiovascular mortality in patients with gout
[52]. A recent study of a large UK primary care
database of patients with gout and matched
controls found that risks for incident
comorbidity were higher not only for
cardiovascular, metabolic/endocrine, and
musculoskeletal diseases, but also for
genitourinary disease, liver diseases,
hemiplegia, depression, anemia, and psoriasis
[21].
In our study, we saw relatively high
incidence rates of several renal and
cardiovascular comorbidities. Using four
different databases provided a range of
estimates for relevant incidence and
prevalence of comorbidities. Each database
had distinct strengths and limitations and
used different resources in different countries
and each estimate needs to be interpreted with
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caution. Some databases may have captured
some comorbidities better than others. Several
limitations to this study deserve discussion.
First, there was variability across the four
countries in prevalent comorbidity and new
incident diagnostic and/or laboratory events.
This could be related to true differences in the
populations, differences in disease course or
treatment intensity between countries, and also
to methodological and other differences in the
databases analyzed. Since we mainly relied on
the diagnosis codes and laboratory-specific data
to select patients with gout and identify their
comorbidities, potential misclassification bias is
as always a caveat and may be different across
the databases. In addition, the prevalence rates
were assessed in a ‘‘gout trial-aligned’’ cohort of
patients with prevalent established gout,
meaning that subjects with some specific
comorbidities of interest (cardiovascular
diseases, liver conditions, severe CKD)
documented 1 year prior to the main index
date had been excluded from the analysis,
which likely resulted in somewhat lower
prevalence rates and, to a more limited extent,
decreased incidence rates of some morbidity
conditions.
Several country-specific limitations to the
study due to the nature of the individual
databases used should also be discussed. In DE,
the percentage of physicians represented (2.4%)
was not a random sample and was small. As a
consequence, the patients sampled might not
be representative of the whole German
population. For the UK data, the prevalence
rates may potentially be somewhat
underestimated, particularly with chronic
conditions, as an artifact of the CPRD database
where patients remain linked to the same
practice for a long time and chronic
conditions may not be documented
repeatedly; to some extent, this was likely
alleviated by the relatively extended look-back
period to 2003 for many pre-index
comorbidities. The US PharMetrics Plus
database is representative of commercially
insured working adults, so generalizability to
older populations (aged C65 years) is limited. In
addition, laboratory data were not directly
available in the database and were acquired
through a third-party vendor, thereby limiting
identification of laboratory values for all
patients in the study and resulting in
outcomes based on laboratory values that may
not be representative of the whole population.
In general, claims data have inherent
limitations as they are collected for billing and
reimbursement purposes rather than for
research purposes. Abnormal laboratory data
are likely underestimated in all databases, since
all patients are not tested, and absence of an
abnormal value cannot automatically be
assumed to imply a normal value. In FR, as in
the US, due to the limitations of availability of
laboratory data for all patients and the nature of
the claims database, some underreporting of
many incidence rates is likely. In addition, some
patients with prevalent gout may self-treat, and
as a result may not always show up in health
databases. Some outcomes that are often
hospitalized may also be underreported where
hospitalizations are not completely captured,
e.g., in FR, and in DE where only referrals but
not emergency hospitalizations are captured in
the database. More generally, the estimated
prevalence rates would be expected to increase
when increasing the look-back period. This is
supported by the UK data, which show that the
crude prevalence of hypertension, which was
32.4% when assessed with 7 years look-back to
January 1, 2003 (Table 2), was 5.7% when
assessed only over the 1-year pre-index period.
Specificity of the outcome definition will also
affect the prevalence estimates, for example the
1194 Adv Ther (2016) 33:1180–1198
estimated crude prevalence of hypertension in
the UK data dropped from 32.4% to 4.6% when
requiring two outpatient visits rather than only
one for the condition. Overall, the retrospective
observational nature of this study, its use of
secondary data, and the analytical definitions
used should be considered when interpreting
the results.
CONCLUSIONS
In summary, it is difficult to quantify an ‘‘exact’’
burden based on these data; nevertheless, this
study fills an important current gap by
providing a range of potentially relevant
estimates of prevalence and incidence of these
conditions, obtained using as consistent
methodology as possible across databases, in a
large real-world setting reflective of today’s
patient populations in these four countries. As
a whole, our findings confirm that there is a
notable degree of renal and cardiovascular
comorbidity burden among patients with
gout. Additionally, the results demonstrate
that patients with gout, followed over time,
continue to be frequently diagnosed with new
significant morbidity events.
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